<?xml version='1.0' encoding='utf-8'?>
<document id="20032126"><sentence text="An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer."><entity charOffset="24-33" id="DDI-PubMed.20032126.s1.e0" text="sunitinib" /><entity charOffset="39-49" id="DDI-PubMed.20032126.s1.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20032126.s1.e0" e2="DDI-PubMed.20032126.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20032126.s1.e0" e2="DDI-PubMed.20032126.s1.e1" /></sentence><sentence text="Sunitinib has shown single-agent activity in patients with previously treated metastatic breast cancer (MBC)"><entity charOffset="0-9" id="DDI-PubMed.20032126.s2.e0" text="Sunitinib" /></sentence><sentence text=" We investigated the safety of the combination of sunitinib and paclitaxel in an exploratory study of patients with locally advanced or MBC"><entity charOffset="50-59" id="DDI-PubMed.20032126.s3.e0" text="sunitinib" /><entity charOffset="64-74" id="DDI-PubMed.20032126.s3.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20032126.s3.e0" e2="DDI-PubMed.20032126.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20032126.s3.e0" e2="DDI-PubMed.20032126.s3.e1" /></sentence><sentence text="" /><sentence text="Patients received oral sunitinib 25 mg/day (with escalation to 37"><entity charOffset="23-32" id="DDI-PubMed.20032126.s5.e0" text="sunitinib" /></sentence><sentence text="5 mg/day as tolerated) on a continuous daily dosing schedule and paclitaxel 90 mg/m(2) on days 1, 8, and 15 of each 28-day cycle"><entity charOffset="65-75" id="DDI-PubMed.20032126.s6.e0" text="paclitaxel" /></sentence><sentence text=" Study endpoints included safety (primary endpoint), pharmacokinetics, and antitumor activity" /><sentence text="" /><sentence text="Twenty-two patients were enrolled" /><sentence text=" The most frequent adverse events (AEs) were fatigue/asthenia (77%), dysgeusia (68%), and diarrhea (64%)" /><sentence text=" Grade 3 AEs included neutropenia (43%), fatigue/asthenia (27%), neuropathy (18%), and diarrhea (14%)" /><sentence text=" No drug-drug interaction was observed on the basis of pharmacokinetic analysis" /><sentence text=" Of 18 patients with measurable disease at baseline, 7 (38" /><sentence text="9%) achieved objective responses (including 2 complete and 5 partial responses)" /><sentence text=" Clinical responses were observed in three of nine patients with triple-negative receptor status (estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor-2 negative)"><entity charOffset="98-106" id="DDI-PubMed.20032126.s15.e0" text="estrogen" /><entity charOffset="126-138" id="DDI-PubMed.20032126.s15.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.20032126.s15.e0" e2="DDI-PubMed.20032126.s15.e0" /><pair ddi="false" e1="DDI-PubMed.20032126.s15.e0" e2="DDI-PubMed.20032126.s15.e1" /></sentence><sentence text="" /><sentence text="These data indicate that sunitinib and paclitaxel in combination are well tolerated in patients with locally advanced or MBC"><entity charOffset="25-34" id="DDI-PubMed.20032126.s17.e0" text="sunitinib" /><entity charOffset="39-49" id="DDI-PubMed.20032126.s17.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.20032126.s17.e0" e2="DDI-PubMed.20032126.s17.e0" /><pair ddi="false" e1="DDI-PubMed.20032126.s17.e0" e2="DDI-PubMed.20032126.s17.e1" /></sentence><sentence text=" No drug-drug interaction was detected and there was preliminary evidence of antitumor activity" /><sentence text="" /></document>